(19)
(11) EP 3 824 876 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.08.2023 Bulletin 2023/31

(45) Mention of the grant of the patent:
22.02.2023 Bulletin 2023/08

(21) Application number: 20199940.6

(22) Date of filing: 17.05.2011
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 31/00(2006.01)
A61K 9/08(2006.01)
A61K 47/02(2006.01)
A61K 38/22(2006.01)
A61P 3/08(2006.01)
A61P 5/50(2006.01)
 A61K 38/00(2006.01)
A61K 38/28(2006.01)
A61K 38/26(2006.01)
A61K 47/10(2017.01)
A61P 3/10(2006.01)
A61K 47/26(2006.01)
A61P 5/48(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0019; A61K 9/08; A61K 38/28; A61K 38/2278; A61K 47/02; A61K 47/10; A61K 47/26; A61K 38/26; A61P 3/08; A61P 5/48; A61P 5/50; A61P 3/10

(54)

LONG-ACTING FORMULATIONS OF INSULINS

INSULINFORMULIERUNGEN MIT LANGZEITWIRKUNG

FORMULATIONS LONGUE DURÉE D'INSULINES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 19.05.2010 EP 10305532
13.07.2010 EP 10305780
10.02.2011 EP 11305140

(43) Date of publication of application:
26.05.2021 Bulletin 2021/21

(60) Divisional application:
23157670.3 / 4218723

(62) Application number of the earlier application in accordance with Art. 76 EPC:
19184732.6 / 3636250
18161680.6 / 3424491
14166877.2 / 2781212
11166415.7 / 2387989

(73) Proprietor: SANOFI
75017 Paris (FR)

(72) Inventors:
  • BECKER, Reinhard
    65926 Frankfurt am Main (DE)
  • HAHN, Annke
    65926 Frankfurt am Main (DE)
  • BODERKE, Peter
    65824 Schwalbach (DE)
  • FUERST, Christiane
    65926 Frankfurt am Main (DE)
  • MUELLER, Werner
    65926 Frankfurt am Main (DE)
  • TERTSCH, Katrin
    65926 Frankfurt am Main (DE)
  • WERNER, Ulrich
    65926 Frankfurt am Main (DE)
  • LOOS, Petra
    65926 Frankfurt am Main (DE)

(74) Representative: Zwicker, Jörk 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)


(56) References cited: : 
   
  • U Werner ET AL: "Insulin Glargine U-100 Has a Favourable Time-Action Profile Compared to U-40 or NPH Insulin in Healthy, Normoglycaemic Dogs", Poster- Abstract 37th Annual Meeting of Endocrine Society of India, 1 January 2007 (2007-01-01), pages 1-2, XP055541301, Retrieved from the Internet: URL:www.endocrinesocietyindia.org [retrieved on 2019-01-14]
  • HOE 901/2004 STUDY INVESTIGATORS GROUP: "Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients", DIABETIC MEDICINE, JOHN WILEY & SONS, LTD, GB, vol. 20, 1 January 2003 (2003-01-01), pages 545-551, XP002671079, ISSN: 0742-3071, DOI: 10.1046/J.1464-5491.2003.00999.X
  • SECNIK BOYE KRISTINA ET AL: "Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes", HEALTH AND QUALITY OF LIFE OUTCOMES, BIOMED CENTRAL, LONDON, GB, vol. 4, no. 1, 11 October 2006 (2006-10-11), page 80, XP021024604, ISSN: 1477-7525, DOI: 10.1186/1477-7525-4-80
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).